Schedule 13G ownership disclosure

BIOCRYST PHARMACEUTICALS INC

Common Stock · CUSIP: 09058V103

Event date: 2025-09-12

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Deerfield Mgmt, L.P.

    Shares: 12,169,000.00 · Class: 5.80%

  • Deerfield Management Company, L.P.

    Shares: 12,169,000.00 · Class: 5.80%

  • Deerfield Partners, L.P.

    Shares: 12,169,000.00 · Class: 5.80%

  • James E. Flynn

    Shares: 12,169,000.00 · Class: 5.80%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193805-25-001316
Form type
SCHEDULE 13G
Filer
BIOCRYST PHARMACEUTICALS INC
CIK
CIK 882796
Filed
Sep 19, 2025
Reporting period
Sep 12, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub